Danaher Completes Acquisition of Masimo Corporation

About this update from Danaher Corporation

WASHINGTON, June 10, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, announced today that it has completed the acquisition of Masimo Corporation, a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care treatment settings. Masimo's trusted brand, advanced sensor technology and AI-enabled patient monitoring bring complementary and powerful new capabilities to the Danaher diagnostics portfolio. As a result of the transaction, Masimo is now a wholly-owned subsidiary of Danaher and Masimo common stock has ceased trading on the Nasdaq Stock Market. Masimo will continue to operate under the Masimo brand and will be a stand-alone operating company within Danaher's Diagnostics segment."Masimo is a strong strategic fit for Danaher. Together, we expect to strengthen our ability to deliver differentiated products in acute care settings and accelerate Masimo's growth and global reach," said Julie Sawyer Montgomery, Executive Vice President of Diagnostics at Danaher. "We are excited to welcome the Masimo team to Danaher."The consideration payable to former Masimo stockholders will be paid in accordance with the terms of the merger agreement, as further described in the definitive transaction materials filed with the U.S. Securities and Exchange Commission.Second Quarter and Full Year 2026 OutlookThere is no change to Danaher's previously communicated second quarter and full-year 2026 guidance range, excluding the expected contribution from Masimo. The Company does not expect a material contribution from Masimo in the second quarter of 2026. The Company intends to update full-year 2026 guidance in connection with its second quarter earnings release to incorporate Masimo's expected contribution.FORWARD-LOOKING STATEMENTS AND OTHER INFORMATIONStatements in this release that are not strictly historical, including the statements regarding the Company's anticipated financial results for the second quarter and full year 2026, expected strengthening of the Company's ability to deliver differentiated products in acute care settings, expected acceleration of Masimo's growth and global reach, and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of t...

View stock analysis, news, and events for Danaher Corporation